An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression To determine the anti-tumor activity of PHA-739358 in patients with Multiple Myeloma (MM) harbouring the t (4;14) translocation.

• Country None
• organs None
• Specialty None

Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma Evaluation of the survival rate at 7 months

• Country None
• organs None
• Specialty None

Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy Assessment of the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy. Antitumor ac...

• Country None
• organs None
• Specialty None

NERVIANO AURA-6202-011 : Essai de phase 2 évaluant l’efficacité du PHA-739358, chez des patients ayant un myélome multiple. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] An exploratory phase II study of PHA-739358 in patients with multiple myeloma harbouring the t(4;14) translocation with or without FGFR3 expression

• Country France
• organs Myélomes
• Specialty Thérapies Ciblées

Estudio Fase I/II de PHA-848125AC administrado diariamente por vía oral durante 14 días consecutivos cada tres semanas en pacientes con glioma maligno recurrente Phase I part: - To determine the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of PHA-848125AC administered orally once daily for 14 consecutive days followed by 7 da...

• Country None
• organs None
• Specialty None

NERVIANO CDKO-125a-006 : Essai de phase 2 évaluant l'efficacité du PHA-848125AC en traitement de 2ème ligne chez des patients ayant un carcinome thymique non opérable, en rechute ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy

• Country France
• organs Système endocrinien - autres
• Specialty Thérapies Ciblées